BPC-157's measured plasma half-life is short. In the most detailed animal pharmacokinetic study published to date, the elimination half-life after intravenous dosing averaged roughly 15 minutes, and stayed under 30 minutes across every dose and both species tested. Yet the research literature discusses its studied effects over hours and days. That looks like a contradiction. It isn't, and understanding why is one of the more genuinely interesting things about this peptide.
What "Half-Life" Actually Measures
Elimination half-life is a narrow, specific measurement: the time it takes for the concentration of a compound in blood plasma to fall by half. It is a property of clearance. It is not a property of effect.
That distinction is the whole story here. Pharmacology splits into two halves that get conflated constantly:
- Pharmacokinetics (PK) describes what the body does to the compound: absorption, distribution, metabolism, excretion. Half-life lives here.
- Pharmacodynamics (PD) describes what the compound does to the body: what it binds, what pathways it engages, and how long those consequences persist.
A compound can be undetectable in the bloodstream long before whatever it set in motion has finished playing out. Reading a half-life number as a "duration of action" number is a category error, not a shortcut.
What the Published Pharmacokinetic Data Reports
The most thorough pharmacokinetic characterization of BPC-157 available is a 2022 study in Frontiers in Pharmacology that examined its pharmacokinetics, distribution, metabolism, and excretion in rats and beagle dogs. Its reported findings:
| Parameter | Reported finding (animal data) |
|---|---|
| Elimination half-life, IV, rats | Approximately 15.2 minutes (mean) |
| Elimination half-life, all doses, both species | Under 30 minutes |
| Dose proportionality | Linear pharmacokinetics across the doses tested |
| Time to peak plasma concentration, IM, rats | Rapid, within roughly 9 minutes |
| Absolute bioavailability, IM | Roughly 14 to 19 percent in rats; roughly 45 to 51 percent in beagle dogs |
| Metabolism | Rapidly cleaved into small peptide fragments; six metabolites identified by mass spectrometry |
| Principal excretion routes | Urine and bile |
These are figures reported in published animal research. They are not dosing instructions, and they do not establish human values.
Two entries deserve a second look. The first is the bioavailability gap: the same route produced roughly three times the systemic exposure in dogs that it did in rats, a useful caution against assuming any of these numbers transfer to humans unchanged.
The second is the metabolite finding. BPC-157 does not simply vanish from plasma; it is cleaved into smaller fragments, six of which were identified. Whether any carry biological activity has not been established. In pharmacology generally, active metabolites are one well-recognized reason a parent compound's half-life understates how long something is still happening.
Why a Short Half-Life Does Not Mean a Short Effect
This gets argued in both directions online, and both are wrong. Some sources treat a short half-life as proof a compound cannot do anything meaningful; others treat it as proof it must be dosed constantly. Neither inference follows from a half-life figure alone. Two drugs whose pharmacology is thoroughly established show why:
- Aspirin. Acetylsalicylic acid has a plasma half-life on the order of 15 to 20 minutes at low doses. Its effect on platelets lasts for days, because it acetylates the COX-1 enzyme irreversibly and platelets have no machinery to synthesize replacement enzyme. The drug is long cleared; the change it made is not.
- Omeprazole. A proton pump inhibitor with a plasma half-life of roughly an hour, dosed once daily, because it binds gastric proton pumps covalently and acid suppression persists until the cell builds new pumps.
Neither example tells you anything about BPC-157 specifically. They illustrate a principle that applies to any compound: when the action involves binding something durably, triggering a signaling cascade, or altering gene expression, the timeline of the effect is set by the biology downstream, not by how quickly the molecule clears.
Other standard mechanisms that decouple half-life from duration of effect include tissue distribution, where concentration at the site of action falls more slowly than in plasma; hysteresis, a lag between peak plasma level and peak observed effect; and active metabolites.
Published mechanistic research on BPC-157 has focused largely on signaling-level activity, including nitric oxide pathway involvement and growth factor receptor signaling associated with new blood vessel formation. That work describes candidate mechanisms under investigation in laboratory and animal models, not evidence of any human outcome.
Gastric Stability Is a Different Property Entirely
Part of why BPC-157 draws attention is a chemical property that has nothing to do with half-life: it is unusually stable in human gastric juice. Sikiric and colleagues, whose group originally derived the sequence from gastric juice, have reported stability exceeding 24 hours there. That is remarkable for a peptide, since most are degraded within minutes by stomach acid and pepsin. The 15-amino-acid sequence (GEPPPGKPADDAGLV, molecular weight roughly 1,419) contains a proline-rich region that resists protease cleavage.
These two facts sit side by side without conflict:
- Gastric stability describes resistance to chemical degradation in one specific, harsh environment. It is the reason an oral form is studied at all.
- Plasma half-life describes how quickly systemic circulation clears the compound once it reaches the blood. Surviving the stomach does nothing to slow renal or biliary clearance afterward.
Conflating the two produces a common online error: the claim that BPC-157's gastric stability implies a long half-life. It implies no such thing. For a fuller comparison of how the routes differ, see our guide to BPC-157 injection versus capsules and oral forms.
What Is Still Unknown in Humans
Here is the honest boundary of the evidence, stated plainly:
- No published human study has characterized BPC-157's elimination half-life, peak plasma concentration, area under the curve, or tissue distribution. Every half-life figure circulating online, including the ones in this article, is an animal figure.
- Subcutaneous bioavailability in humans, the route most relevant to compounded injectable preparations, has not been published.
- Whether the identified metabolites are inert or active is unresolved.
- No controlled human dose-ranging study exists, so there is no published human pharmacokinetic basis for selecting a dose or a dosing interval.
That last point is where half-life discussions most often go wrong in practice. Any prescription is an individualized clinical judgment made by a licensed provider after evaluation, not an arithmetic result read off a half-life value. Our dosing and handling guide covers what the literature does and does not document there.
Regulatory Status as of July 2026
On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157 to the 503A Bulks List, by 8 in favour, 6 against, and 1 abstention, against FDA staff's own pre-meeting recommendation not to add it.
PCAC recommendations are advisory and non-binding. Before anything changes, the FDA must complete notice-and-comment rulemaking, a process that can take 12 months or more. Nothing has changed yet in what may lawfully be compounded. BPC-157 remains a compounded research peptide that is not FDA-approved for any indication.
How TelosRX Approaches It
Because the human pharmacokinetic picture is genuinely incomplete, TelosRX publishes no protocol. You complete an online intake, a US-licensed provider reviews it and determines clinical appropriateness, and if appropriate issues a prescription specifying format, strength, and directions. Approval is not guaranteed. Product background is on our BPC-157 page.
Frequently Asked Questions
What is BPC-157's half-life?
In published animal research, the elimination half-life of BPC-157 after intravenous dosing in rats averaged roughly 15 minutes, and was reported as under 30 minutes across all doses tested in both rats and beagle dogs. No human pharmacokinetic study characterizing BPC-157's half-life has been published, so no verified human figure exists.
If the half-life is about 15 minutes, does BPC-157 stop doing anything after 15 minutes?
Half-life measures how fast a compound clears from blood plasma, not how long its effects persist. In pharmacology generally, those two timelines routinely diverge: aspirin clears in roughly 15 to 20 minutes but affects platelets for days, because the change it makes to an enzyme outlasts the drug itself. Whether and how that decoupling applies to BPC-157 in humans has not been established, since human pharmacokinetic and pharmacodynamic data has not been published.
Does BPC-157's stability in stomach acid mean it has a long half-life?
No. These are two different properties. Stability in gastric juice, reported at over 24 hours for BPC-157, describes resistance to chemical breakdown in the stomach. Plasma half-life describes clearance from the bloodstream. A compound can be highly stable in gastric juice and still be cleared from plasma within minutes, which is what the available data describes.
How is BPC-157 eliminated from the body?
The 2022 animal pharmacokinetic study reported that BPC-157 is rapidly metabolized into a range of small peptide fragments, with six metabolites identified by mass spectrometry, and that urine and bile are the principal excretion routes. Whether any of those fragments retain biological activity has not been determined.
Is there human pharmacokinetic data for BPC-157?
Not in any meaningful sense. Published pharmacokinetic characterization is animal data. Human subcutaneous bioavailability, tissue distribution, and clearance have not been published, and no controlled human dose-ranging study exists. The bioavailability difference between rats and dogs in the same study is a reminder that animal figures should not be assumed to carry over to people.
Does the half-life tell me how often BPC-157 should be dosed?
No. Dosing intervals for approved drugs are derived from human pharmacokinetic and pharmacodynamic studies, and for BPC-157 those human studies have not been published. Any dosing decision is an individualized clinical judgment made by a licensed provider after evaluation, and should follow the directions on your pharmacy label rather than any calculation based on a half-life figure.
BPC-157 is a compounded research peptide and is not FDA-approved for any indication. Compounded medications are prepared under federal compounding regulations and are available by prescription only after review by a US-licensed provider; approval is not guaranteed. Nothing in this article is dosing advice, and the pharmacokinetic figures described are reported animal research findings, not human values. Individual results vary. TelosRX is LegitScript-certified and operates as an online-first, asynchronous telehealth service.